IPN Ipsen SA

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 48 - 2025

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 48 - 2025

Présentation agrégée par jour et par marché



Déclaration des transactions sur actions propres réalisées du 24 Novembre au 28 Novembre 2025
       
Nom de l'émetteurCode identifiant de l'émetteur (code LEI)Jour de la transactionCode identifiant de l'instrument financierVolume total journalier (en nombre de titres)Prix pondéré moyen journalier d'acquisitionCode identifiant marché
IPSEN549300M6SGDPB4Z94P1124/11/2025FR0010259150300128,00000AQEU
IPSEN549300M6SGDPB4Z94P1124/11/2025FR00102591501000127,96010CEUX
IPSEN549300M6SGDPB4Z94P1124/11/2025FR0010259150300128,00000TQEX
IPSEN549300M6SGDPB4Z94P1124/11/2025FR00102591502600127,79612XPAR
IPSEN549300M6SGDPB4Z94P1125/11/2025FR0010259150300128,80000AQEU
IPSEN549300M6SGDPB4Z94P1125/11/2025FR00102591501300128,38462CEUX
IPSEN549300M6SGDPB4Z94P1125/11/2025FR0010259150300128,80000TQEX
IPSEN549300M6SGDPB4Z94P1125/11/2025FR00102591502400127,92954XPAR
IPSEN549300M6SGDPB4Z94P1126/11/2025FR0010259150600125,90000AQEU
IPSEN549300M6SGDPB4Z94P1126/11/2025FR00102591501000126,02000CEUX
IPSEN549300M6SGDPB4Z94P1126/11/2025FR0010259150300126,00000TQEX
IPSEN549300M6SGDPB4Z94P1126/11/2025FR00102591502879126,22720XPAR
IPSEN549300M6SGDPB4Z94P1127/11/2025FR0010259150500125,16000AQEU
IPSEN549300M6SGDPB4Z94P1127/11/2025FR00102591501000125,35000CEUX
IPSEN549300M6SGDPB4Z94P1127/11/2025FR0010259150300125,50000TQEX
IPSEN549300M6SGDPB4Z94P1127/11/2025FR00102591502312125,52042XPAR
IPSEN549300M6SGDPB4Z94P1128/11/2025FR0010259150300125,40000AQEU
IPSEN549300M6SGDPB4Z94P1128/11/2025FR00102591501000125,00000CEUX
IPSEN549300M6SGDPB4Z94P1128/11/2025FR0010259150300125,00000TQEX
IPSEN549300M6SGDPB4Z94P1128/11/2025FR00102591502357124,98990XPAR
    21 348126,54644 

Pièce jointe



EN
02/12/2025

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen expands early development pipeline with Simcere Zaiming’s innova...

Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a LRRC15-targeting antibody-drug conjugateSIM0613 is optimally designed for superior tumor penetration with robust preclinical efficacy dataProgram expected to enter Phase I clinical development in H2 2026Simcere Zaiming is eligible to receive up to $1.06B in total payments PARIS, FRANCE; 22 DECEMBER 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today an exclus...

December 22, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen élargit son portefeuille de produits en développement précoce av...

Ipsen élargit son portefeuille de produits en développement précoce avec un conjugué anticorps-médicament innovant développé par Simcere Zaiming Ipsen obtient les droits mondiaux exclusifs, en dehors de la Grande Chine, pour le développement, la fabrication et la commercialisation de SIM0613, un conjugué anticorps-médicament ciblant le récepteur LRRC15.SIM0613 est conçu de manière optimale pour une pénétration intra-tumorale supérieure, étayée par des données d’efficacité précliniques probantes.Le programme devrait entrer en Phase I de développement clinique au second semestre 2026. Simcere...

December 22, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen update on Phase II FALKON trial in patients with ultra-rare bone...

Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP) PARIS, FRANCE, 19 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and children living with fibrodysplasia ossificans progressiva (FOP) vs. placebo, as a result the study will be closed. The investigational medicinal product (fidrisertib) was generally well tolerated, with no safety concerns in the trial. “These results are ...

December 19, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen fait le point sur l'essai de Phase II FALKON chez les patients a...

Ipsen fait le point sur l'essai de Phase II FALKON chez les patients atteints d’une maladie osseuse ultra-rare, la fibrodysplasie ossifiante progressive (FOP) PARIS, FRANCE – 19 décembre 2025 – Ipsen (Euronext : IPN ; ADR : IPSEY) annonce aujourd'hui que l'essai pivotal de Phase II FALKON n'a pas atteint son critère principal, à savoir la réduction du volume de formation anormale de nouvelle matière osseuse (ossification hétérotopique ou OH) chez l’adulte et l’enfant atteints de fibrodysplasie ossifiante progressive (FOP), par rapport au placebo, en conséquence, l'étude sera clôturée. Le mé...

December 19, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncolog...

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 year...

December 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch